ADS024, a Bacillus velezensis strain, protects human colonic epithelial cells against C. difficile toxin-mediated apoptosis
Authors:
Open Access
- 10 January 2023
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 13, 1072534
Abstract
Clostridioides difficile infection (CDI) causes intestinal injury. Toxin A and toxin B cause intestinal injury by inducing colonic epithelial cell apoptosis. ADS024 is a Bacillus velezensis strain in development as a single-strain live biotherapeutic product (SS-LBP) to prevent the recurrence of CDI following the completion of standard antibiotic treatment. We evaluated the protective effects of the sterile filtrate and ethyl acetate extract of conditioned media from ADS024 and DSM7 (control strain) against mucosal epithelial injury in toxin-treated human colonic tissues and apoptosis in toxin-treated human colonic epithelial cells. Ethyl acetate extracts were generated from conditioned culture media from DSM7 and ADS024. Toxin A and toxin B exposure caused epithelial injury in fresh human colonic explants. The sterile filtrate of ADS024, but not DSM7, prevented toxin B-mediated epithelial injury in fresh human colonic explants. Both sterile filtrate and ethyl acetate extract of ADS024 prevented toxin-mediated apoptosis in human colonic epithelial cells. The anti-apoptotic effects of ADS024 filtrate and ethyl acetate extract were dependent on the inhibition of caspase 3 cleavage. The sterile filtrate, but not ethyl acetate extract, of ADS024 partially degraded toxin B. ADS024 inhibits toxin B-mediated apoptosis in human colonic epithelial cells and colonic explants.Keywords
This publication has 43 references indexed in Scilit:
- Fidaxomicin Versus Vancomycin for Clostridium difficile Infection: Meta-analysis of Pivotal Randomized Controlled TrialsClinical Infectious Diseases, 2012
- Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trialThe Lancet Infectious Diseases, 2012
- Clostridium difficile Toxins: Mediators of InflammationJournal of Innate Immunity, 2012
- The role of toxin A and toxin B in Clostridium difficile infectionNature, 2010
- Expression of recombinant Clostridium difficile toxin A and B in Bacillus megateriumBMC Microbiology, 2008
- Comparative analysis of the complete genome sequence of the plant growth–promoting bacterium Bacillus amyloliquefaciens FZB42Nature Biotechnology, 2007
- Substance P mediates antiapoptotic responses in human colonocytes by Akt activationProceedings of the National Academy of Sciences, 2007
- Purification and Characterization of Proteases from Bacillus amyloliquefaciens Isolated from Traditional Soybean Fermentation StarterJournal of Agricultural and Food Chemistry, 2003
- Mechanism ofClostridium difficileToxin A–Induced Apoptosis in T84 CellsThe Journal of Infectious Diseases, 2002
- Caspase-3 Is Required for DNA Fragmentation and Morphological Changes Associated with ApoptosisJournal of Biological Chemistry, 1998